Royal Philips (PHG) on Monday said it was expanding its partnership with Ibex Medical Analytics, further integrating Ibex's artificial intelligence tools for detecting and diagnosing prostate, breast, and gastric cancer into its IntelliSite Pathology scanners and image management systems.
Philips and Ibex began their partnership in 2021. Philips' IntelliSite Pathology platform received 510(k) clearance from the US Food and Drug Administration in July 2024, while Ibex received 510(k) clearance on Feb. 10 for its Prostate Detect, an in-vitro diagnostic device using AI to generate heatmaps identifying small and often-missed prostatic cancers.
Philips earlier this month also disclosed a collaboration with Amazon (AMZN) Web Services to offer cloud archival services for pathology labs, supporting efficient and secure storage and management of digital pathology data.
The company will be demonstrating its Philips IntelliSite Pathology Solution 6.0 at an industry conference now underway and running through Thursday in Boston, it said.
Price: 25.46, Change: -0.03, Percent Change: -0.13
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。